Michael J. Overman, MD
Updated findings from the CheckMate-142 study presented at the 2018 Gastrointestinal Cancers Symposium continued to support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
at the symposium, Overman, associate professor in the Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed both the updated findings he presented at the meeting for the single-agent CheckMate-142 cohort, as well as the latest combination data from the pivotal trial.
OncLive: Can you please provide some background information on this study?
This an updated analysis of the CheckMate-142 study. The main arm in that was single-agent nivolumab in a 2-stage design, where we evaluated the idea of using anti–PD-1 therapy in this population, which is dMMR/MSI-H mCRC. Therefore, dMMR patients have a deficiency in DNA repair, which leads to a lot of mutations. There was a hypothesis that this group would be responsive to immune-based therapy, and that is how this study initiated.
... to read the full story